People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eyevance Holdings LLC | — | Other | Series B | $30.0M | $498.6M | 2019 |
| InflammX Therapeutics, Inc. | — | Biotechnology | Series A | $15.4M | $156.2M | 2021 |
| SightStream Biotherapeutics, Inc. | — | Biotechnology | Seed | $5.1M | $4.3M | 2022 |
Jason Werner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jason Werner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian Levy | 1 | 8 |
| James Blair | 1 | 8 |
| David Neafus | 1 | 7 |
| Thomas Vandervort | 1 | 4 |
| David Pool | 1 | 4 |
| Reza Dana | 1 | 3 |
| Rajiv Shukla | 1 | 2 |
| Wenkai Xiang | 1 | 2 |
| Matthew Heck | 1 | 2 |
| Wes Brazell | 1 | 2 |
| James Flexner | 1 | 2 |
| Samuel Wu | 1 | 2 |
| Terence Cook | 1 | 1 |
| Jiagang Zhao | 1 | 1 |
| David Boyer | 1 | 1 |
| Phil Rosenfeld | 1 | 1 |
| Jerry St. Peter | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.